News | Radiopharmaceuticals and Tracers | March 01, 2016

Company part of U.S. Department of Energy efforts to establish a reliable domestic supply of key radioisotope

March 1, 2016 — Wisconsin-based Shine Medical Technologies Inc., producer of medical tracers and cancer treatment elements, announced that the U.S. Nuclear Regulatory Commission (NRC) has authorized issuance of the Shine construction permit. With the construction permit in hand, Shine has federal regulatory approval to begin construction of its approximately 57,000-square-foot medical isotope manufacturing facility in Janesville, Wis.

Shine is the only U.S. medical isotope producer to have reached this stage of the NRC permitting process since the 1960s.

The issuance of the construction permit is the culmination of more than four years of effort by both Shine and the NRC. It follows two years of environmental data collection and safety analysis by Shine, as well as two years of rigorous safety and environmental reviews by the NRC.

Shine’s work is supported by the Department of Energy’s National Nuclear Security Administration’s molybdenum-99 program, which seeks to develop reliable and sustainable domestic production of molybdenum-99 (moly-99) without the use of highly enriched uranium. Molybdenum-99 (moly-99) is a radioisotope that decays into the diagnostic imaging agent technetium-99m (tech-99m). Tech-99m is used in more than 40 million medical imaging procedures each year, primarily in stress tests to diagnose heart disease and bone scans to stage cancer.

Despite constituting approximately half of world demand for moly-99, the United States does not produce any moly-99 domestically and imports 100 percent of its supply from foreign nuclear reactors. The majority of these reactors are beyond their original design life and scheduled to be shut down in the coming years. Previous outages of these aging facilities have caused major isotope shortages, significantly impacting patient care.

Founded in 2010, Shine is a development-stage company working toward becoming a manufacturer of radioisotopes for nuclear medicine. The Shine system uses a patented, proprietary manufacturing process that does not require a nuclear reactor, uses less electricity, generates less waste and is compatible with the nation’s existing supply chain for moly-99.

Shine is one of four commercial projects that the U.S. Department of Energy, National Nuclear Security Administration established partnerships with since 2010 to accelerate the establishment of a reliable U.S. domestic supply of molybdenum-99 produced without the use of highly enriched uranium.

In 2014, SHINE announced the execution of moly-99 supply agreements with GE Healthcare and Lantheus Medical Imaging. In 2015, with the help of Argonne National Laboratory, GE Healthcare demonstrated SHINE moly-99 can act as a drop-in replacement for reactor-based moly-99.

For more information: www.shinemed.com


Related Content

News | Quality Assurance (QA)

November 25, 2023 — Mirion announced that it will debut the new Instadose VUE personal dosimeter, from its Dosimetry ...

Time November 25, 2023
arrow
News | PET Imaging

November 8, 2023 — In a small study, researchers at the National Institutes of Health have found that positron emission ...

Time November 08, 2023
arrow
News | Linear Accelerators

October 25, 2023 — A new order for several Elekta Harmony linear accelerators (linacs) in Ukraine will complement the ...

Time October 25, 2023
arrow
News | Proton Therapy

October 23, 2023 — IBA, a world leader in particle accelerator technology and the world’s leading provider of proton ...

Time October 23, 2023
arrow
News | Radiopharmaceuticals and Tracers

October 20, 2023 — Meilleur Technologies, Inc. announced a research collaboration agreement with the Alzheimer’s Disease ...

Time October 20, 2023
arrow
News | Radiation Therapy

October 19, 2023 — The lung is one of the tissues most sensitive to radiation in the human body. People exposed to high ...

Time October 19, 2023
arrow
News | Radiopharmaceuticals and Tracers

October 18, 2023 —ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Canadian ...

Time October 18, 2023
arrow
News | Radiation Oncology

October 17, 2023 — Radionetics Oncology, Inc., a clinical stage radiopharmaceutical company focused on the discovery and ...

Time October 17, 2023
arrow
News | Radiopharmaceuticals and Tracers

October 11, 2023 — GE HealthCare today announced an exclusive global licensing agreement with SOFIE Biosciences (SOFIE) ...

Time October 11, 2023
arrow
News | Breast Imaging

October 11, 2023 — A new imaging agent, 68Ga-ABY-025, can predict early metabolic response to human epidermal growth ...

Time October 11, 2023
arrow
Subscribe Now